These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36798114)

  • 1. SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus.
    Alkayyal AA; Ajina R; Cacciabue M; Alkayyal AA; Saeedi NH; Hussain Alshehry T; Kaboha F; Alotaibi MA; Zaidan N; Shah K; Alroqi F; Bakur Mahmoud A
    Front Immunol; 2023; 14():1082191. PubMed ID: 36798114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.
    Goel A; Carlson SK; Classic KL; Greiner S; Naik S; Power AT; Bell JC; Russell SJ
    Blood; 2007 Oct; 110(7):2342-50. PubMed ID: 17515401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
    Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
    Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
    Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
    J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis Virus.
    Gao Y
    DNA Cell Biol; 2024 Feb; 43(2):57-60. PubMed ID: 38079267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
    Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
    Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
    Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
    Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
    Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.
    Ammayappan A; Peng KW; Russell SJ
    J Virol; 2013 Dec; 87(24):13543-55. PubMed ID: 24089573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.
    Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
    Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
    Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Cycle Arrest in G
    Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.